Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease
Clinical trial NCT02218489 · COMPLETED
Trial details
- NCT number
- NCT02218489
- Sponsor
- Kala Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-01
- Primary completion
- 2015-12-01
- Enrollment
- 206
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.